Minority variants of drug-resistant HIV.

The Journal of Infectious Diseases
Sara Gianella, D D Richman

Abstract

Minor drug-resistant variants exist in every patient infected with human immunodeficiency virus (HIV). Because these minority variants are usually present at very low levels, they cannot be detected and quantified using conventional genotypic and phenotypic tests. Recently, several assays have been developed to characterize these low-abundance drug-resistant variants in the large, genetically complex population that is present in every HIV-infected individual. The most important issue is what results generated by these assays can predict clinical or treatment outcomes and might guide the management of patients in clinical practice. Cutoff values for the detection of these low-abundance viral variants that predict an increased risk of treatment failure should be determined. These thresholds may be specific for each mutation and treatment regimen. In this review, we summarize the attributes and limitations of the currently available detection assays and review the existing information about both acquired and transmitted drug-resistant minority variants.

References

Aug 26, 1988·Science·U LandegrenL Hood
Jul 1, 1995·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·P S EastmanJ Kolberg
Jul 1, 1993·Scientific American·M Eigen
Apr 22, 1993·The New England Journal of Medicine·A EriceH H Balfour
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·L MoutouhD D Richman
Nov 13, 1998·Proceedings of the National Academy of Sciences of the United States of America·D V NissleyJ N Strathern
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·J W Drake, J J Holland
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·C J PetropoulosJ M Whitcomb
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·W ReschR Swanstrom
Feb 7, 2001·Journal of Clinical Microbiology·D O'MearaJ Lundeberg
Feb 28, 2002·AIDS Research and Human Retroviruses·Rob SchuurmanUNKNOWN ENVA Working Group
Jun 28, 2002·The New England Journal of Medicine·Sharon WalmsleyUNKNOWN M98-863 Study Team
Aug 9, 2002·The New England Journal of Medicine·Susan J LittleDouglas D Richman
Aug 29, 2003·The New England Journal of Medicine·Jody LawrenceUNKNOWN 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS
Apr 9, 2004·Journal of the American Chemical Society·Christopher B SherrillJames R Prudent
Jul 13, 2004·The New England Journal of Medicine·Gonzague JourdainUNKNOWN Perinatal HIV Prevention Trial Group
Jul 29, 2004·AIDS·Bluma BrennerUNKNOWN Co-Investigators of the Quebec Primary Infection Study
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard E NettlesRobert F Siliciano
Dec 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Denise LecossierAllan J Hance

❮ Previous
Next ❯

Citations

Apr 7, 2011·JAMA : the Journal of the American Medical Association·Jonathan Z LiDaniel R Kuritzkes
Jul 13, 2013·The Journal of Infectious Diseases·Karin J MetznerUNKNOWN Swiss HIV Cohort Study
Oct 23, 2012·The Journal of Antimicrobial Chemotherapy·Farbod BabrzadehRobert W Shafer
Mar 8, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Dara A LehmanJulie Overbaugh
Sep 30, 2010·Antimicrobial Agents and Chemotherapy·Birgit SchindeleBernhard Ehlers
Jun 12, 2012·PLoS Computational Biology·Pleuni Simone Pennings
Jul 23, 2013·PloS One·Anna Maria GerettiUNKNOWN INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group
May 14, 2014·Annual Review of Genomics and Human Genetics·Shiven B ChabriaMichael J Kozal
Feb 26, 2015·Pathology·Theo P SlootsJonathan R Iredell
Jun 27, 2015·Current Opinion in Virology·Kristel Van LaethemAnne-Mieke Vandamme
Sep 1, 2015·The Journal of Molecular Diagnostics : JMD·Lei ZhangAnubhav Tripathi
Apr 16, 2014·Journal of Virological Methods·Birgitte B SimenUNKNOWN 454 HIV Alphastudy Group
Apr 28, 2016·Proceedings of the National Academy of Sciences of the United States of America·Annalaura BraiMaurizio Botta
Oct 4, 2016·Virus Research·Susana Posada-CespedesNiko Beerenwinkel
Nov 8, 2016·Virus Research·Maria Casadellà, Roger Paredes
May 31, 2014·International Journal of STD & AIDS·Andrew M HillRalph DeMasi
Mar 24, 2016·Antimicrobial Agents and Chemotherapy·Fred KyeyuneMiguel E Quiñones-Mateu
Dec 17, 2014·Current Opinion in Infectious Diseases·Anna Maria GerettiMichael J Kozal
Nov 16, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Manon Ragonnet-CroninJames I Brooks
Oct 1, 2018·Applied Microbiology and Biotechnology·Francesca Marino-MerloSandro Grelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.